Can you be on Wegovy long term, and what does the evidence say?

What the STEP trials established about sustained semaglutide use

The STEP 1 trial, published in the New England Journal of Medicine, ran for 68 weeks and recorded an average body-weight reduction of around 15% with semaglutide 2.4mg. That figure alone answers part of the long-term question: it took more than a year of treatment to reach that average, which tells you this medicine works over sustained periods rather than in weeks. The STEP 4 extension trial went further. Participants who had already lost weight on semaglutide were randomised either to continue or switch to placebo: those who continued maintained most of their loss, while those who stopped regained around two-thirds of it within a year. That evidence is the clinical foundation for the view that semaglutide is a long-term treatment, not a course you finish. If you want a detailed look at whether Wegovy works long term and what the evidence actually shows, the patterns from STEP 4 are central to that answer. It works in the body while you take it, and its effects reverse substantially when you stop, a pattern the NHS semaglutide guidance acknowledges when it notes that treatment is usually ongoing.

The two-year NICE cap: what it means for you in practice

NICE's appraisal of Wegovy (TA875) recommends it only within specialist weight management services on the NHS and sets a ceiling of two years of treatment. It is worth being precise about what that means. The two-year limit is a condition of the NHS recommendation, attached to NHS commissioning and cost-effectiveness modelling. It does not override the medicine's licensed indication, which does not specify a fixed treatment duration. The SmPC and prescriber guidance describe Wegovy as a long-term weight-management medicine; the two-year boundary is an NHS resource decision, not a safety verdict. For people accessing treatment through a regulated private route, the relevant question is whether the prescriber considers continued treatment clinically appropriate, assessed each time a repeat is requested. A question our prescribers hear most weeks is whether someone will need to stay on it long term: the honest clinical answer is that it depends on the individual, their weight trajectory, their comorbidities and their response, and it changes over time.

Monitoring and safety during extended semaglutide use

Long-term use does not mean low-scrutiny use. The MHRA issued a Drug Safety Update in January 2026 reinforcing that acute pancreatitis is a known, infrequent but serious risk: severe stomach pain that may travel to the back, with or without vomiting, warrants urgent medical attention. You can report any suspected side effects through the MHRA Yellow Card scheme. Beyond pancreatitis, the side-effect profile of semaglutide is largely gastrointestinal (nausea, loose stools, constipation, reflux) and these are most noticeable in the early months or after a dose increase, typically settling as the body adjusts. Over longer treatment periods, the goal shifts from tolerating dose escalation to maintaining weight at a stable therapeutic dose. Prescribers look at whether you are still benefiting, whether any new health factors have emerged, and whether lifestyle changes are being sustained alongside the medicine. That review process is part of why the long-term effects of Wegovy are better understood now than they were at launch, and why evidence continues to accumulate. There is also the newer Wegovy 7.2mg dose approved by the MHRA in April 2026, higher maintenance doses may be relevant for some people over the longer term, subject to clinical assessment at each review.

What stopping looks like, and the cost context of long-term treatment

Deciding to stop Wegovy is a clinical conversation, not a personal failure. The evidence from STEP 4 is clear that weight often returns, which means stopping is a planned decision with a plan for what comes next, not something to do abruptly or without guidance. Some people stop because they have hit a sustained healthier weight and want to maintain it through diet and activity alone; some stop because of side effects; some reach the end of an NHS-funded period and face a decision about continuing privately. The cost of long-term private treatment is a real consideration. If you are weighing up whether sustained semaglutide treatment makes financial sense, our breakdown of Wegovy costs in the UK covers what the market currently looks like and what a legitimate private prescription should include. One thing is consistent: the right measure for a long-term prescription medicine is not price alone. It is clinical oversight, genuine supply chain, and a prescriber who re-reviews your case before every repeat. If you are considering continuing Wegovy beyond your initial treatment period and want a same-day clinical review, speak to our prescribers and we will assess your suitability properly.